Sampada Potdar*
Dr. A. H. Hosmani
Glaucoma is a complex visual disorder characterized by an increase in intraocular pressure (IOP), which can eventually lead to progressive vision loss. [1] This condition is occurs by gradual degeneration of retinal cells and optic nerve fibers, leading to vision impairment. [2] A key characteristic of glaucoma is the gradual narrowing of peripheral vision, which distinguishes it from other visual disorders. In many cases, glaucoma remains asymptomatic until routine eye examinations reveal early signs. [3] Acute angle-closure glaucoma, however, can manifest rapidly, resulting in a sudden and severe loss of vision, often accompanied by symptoms such as headache, nausea, vomiting, corneal swelling, and intense eye pain. Secondary glaucoma, on the other hand, is usually caused by an underlying eye injury or medical condition that increases intraocular pressure [4] There are several types including congenital, pigmentary, neovascular, exfoliative, traumatic, and uveitic variants. [5] While elevated IOP is commonly associated with glaucoma, some individuals may experience vision loss without significant IOP changes, a condition known as normal-tension glaucoma. The majority of glaucoma cases are diagnosed in individuals aged 40 and above, while congenital, developmental, and juvenile forms typically impact younger populations. [6] [7] Glaucoma management typically involves a combination of medication, laser therapy, or surgical intervention, all aimed at lowering intraocular pressure and slowing disease progression. Although these treatments cannot reverse existing optic nerve damage or restore lost visual fields, they can effectively reduce further deterioration. By actively treating affected individuals, healthcare providers strive to minimize vision loss and preserve quality of life. [8]
Epidemiology: [9]
In 2010, an estimated 2.1 million individuals, accounting for 6-5% of the 32.4 million blind people worldwide, were blind due to glaucoma. This condition, primarily affecting older adults, displayed a lower prevalence in younger regions but was more commonly observed in high-income areas with aging populations. Among individuals aged 40 to 80 years, the global prevalence of glaucoma was approximately 3-5%. Specifically, primary open-angle glaucoma affected around 3.1% of this age group, making it nearly six times more common than primary angle-closure glaucoma, which had a prevalence of approximately 0.5%. Demographically, individuals of African descent were more likely to develop primary open-angle glaucoma compared to those of European ancestry, with an odds ratio of 1.36. Gender also played a role, with men having a higher likelihood (OR 2.80) of developing the condition compared to women. Additionally, bilateral blindness caused by glaucoma was observed more frequently in individuals with primary angle-closure glaucoma than those with open-angle glaucoma, suggesting a potentially worse prognosis for the former.
What is Glaucoma: [10] [11][12][13][14]
Glaucoma is a chronic, progressive eye disease characterized by damage to the optic nerve, usually caused by increased intraocular pressure (IOP). This damage leads to gradual loss of peripheral vision, and if left untreated, it can result in permanent blindness. Glaucoma is often called the "silent thief of sight" because it typically develops without noticeable symptoms until advanced stages. Early detection and treatment are crucial to prevent vision loss.
10.5281/zenodo.15721569